- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05153967
Spółdzielcza ocena późnych skutków terapii leczniczych SCD (COALESCE)
U01 Spółdzielcza ocena późnych skutków terapii leczących anemię sierpowatokrwinkową
Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births. Approximately 100,000 individuals are diagnosed with SCD in the United States. Mortality for children with SCD has decreased substantially over the past 4 decades, with >99% of those born in high resource settings, including the United States, France, and England, now surviving to 18 years of age. However, the life expectancy of adults with SCD is severely shortened. Dysfunction of the heart, lung, and kidney is directly associated with decreased life expectancy. With the variety of curative therapies that are now available for SCD, long-term health outcomes studies are time-sensitive. As of now, efforts to determine long-term health outcomes following curative therapies for SCD have been limited. Though curative therapies initially should provide a cure for symptoms of SCD, there is the risk of late health outcomes to consider. Defining health outcomes following curative therapy is essential to improve personalized decision-making when considering curative versus disease-modifying therapeutic options. The primary goal of this study is to determine whether curative therapies for individuals with SCD will result in improved or worsening heart, lung, and kidney damage when compared to individuals with SCD receiving standard therapy. The investigators will also explore whether certain genes are associated with a good or bad outcome after curative therapy for SCD.
Przegląd badań
Status
Szczegółowy opis
Our primary objective is initiating a personalized approach to curative therapies in children and adults with sickle cell disease (SCD) to maximize benefits and limit adverse outcomes. Limited clinical studies exist to determine the long-term health outcomes following curative therapies for SCD. With emerging curative therapies for SCD (allogeneic [allo] hematopoietic stem cell transplant [HSCT], gene therapy/editing), long-term health outcomes studies are critical to inform personalized choices. Unfortunately, adverse outcomes have started to emerge after SCD curative therapy. Thus, risks of a cure in SCD must be measured against the benefits of a cure, including stabilization of lung function (FEV1) and improved tricuspid regurgitant jet velocity [TRJV]. Ultimately, the shortened lifespan of individuals with SCD, attributable to declining heart (elevated TRJV), lung (decreased FEV1), and kidney (decreased eGFR) function, for which curative therapies were designed to ameliorate, must be measured against favorable and unfavorable late outcomes. In our multicenter retrospective-prospective cohort, the investigators will test the following hypotheses: 1a): myeloablative curative therapies for children with SCD will result in progressive pulmonary and renal dysfunction when compared to children with SCD receiving standard therapy; 1b): nonmyeloablative HSCT for adults with SCD will result in no significant change in FEV1% predicted, but will lead to accelerated decline in eGFR when compared to adults receiving standard therapy; 2) nonmyeloablative HSCT for adults with SCD will be associated with a clinically significant improvement in TRJV following HSCT; and 3) in adults with SCD, proliferative and genotoxic stress uniformly related to nonmyeloablative allo-HSCT and myeloablative gene editing will lead to post-HSCT therapy-related myeloid neoplasm of recipient origin. The investigators will address these hypotheses with the following aims: 1) evaluate the incidence of pulmonary and renal function in 1a: children with SCD receiving myeloablative curative therapies; and 1b: adults with SCD receiving nonmyeloablative allo-HSCT, compared to a pre-existing cohort of children and adults with SCD; 2) determine whether there is a clinically significant improvement in TRJV in adults with SCD, at least half having TRJV > 2.5 m/s, following nonmyeloablative allo-HSCT, 3) evaluate the prevalence, incidence and evolution of Clonal hematopoiesis of indeterminate potential (CHIP) concerning therapy-related myeloid neoplasm development following non-myeloablative HSCT or myeloablative gene editing in adults and children with SCD, and 4) evaluate accuracy and gaps involved in collecting clinical health record data directly from patients and family members in comparison to clinical health record data collected by research coordinators.
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20010
- Children's National Medical Center
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30322
- Emory University School of Medicine
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21287
- Johns Hopkins Hospital
-
Bethesda, Maryland, Stany Zjednoczone, 20814
- National Institutes of Health Clinical Center
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone, 37232-9000
- Vanderbilt University Medical Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Participants will be patient volunteers from the sickle cell disease clinics and transplant centers of participating study sites.
Opis
Inclusion Criteria
- Confirmed laboratory diagnosis of SCD
- Ability to give informed consent
- Ability to provide pre- and post-curative therapy data
- Treated with either one HSCT or with standard disease-modifying therapy
Exclusion Criteria
•History of non-compliance
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: OTHER
Kohorty i interwencje
Grupa / Kohorta |
|---|
|
Pediatric Myeloablative allo-HSCT
Participants ages 4 to 17 years old with SCD who underwent or are scheduled to undergo myeloablative allo-HSCT. |
|
Pediatric Standard Disease-Modifying Therapy
Participants ages 4 to 17 years old with SCD who receive standard therapy. |
|
Adult Non-Myeloablative allo-HSCT
Participants ages 18 to 65 years old with SCD who underwent or are scheduled to undergo non-myeloablative allo-HSCT. |
|
Adult Standard Disease-Modifying Therapy
Participants ages 18 to 65 years old with SCD who receive standard therapy. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Measurement of longitudinal change in FEV1
Ramy czasowe: Through study completion, an average of four years
|
Measurements of forced expiratory volume in 1 second (FEV1) based on the global lung index will be acquired from children with SCD receiving myeloablative curative therapies and adults with SCD receiving nonmyeloablative allo-HSCT, as well as from the respective control children and adult cohorts with SCD who received standard therapy. FEV1 will be reported in liters. (References: Eur Respir J. Volume 40 Issue 6: pages 1324-1343, 2012 June 27; Am J Hematol. Volume 93 Issue 3: pages 408-415, 2018 March). |
Through study completion, an average of four years
|
|
Percent predicted value of longitudinal change in FEV1
Ramy czasowe: Through study completion, an average of four years
|
Percent predicted of forced expiratory volume in 1 second (FEV1) based on the global lung index will be acquired from children with SCD receiving myeloablative curative therapies and adults with SCD receiving nonmyeloablative allo-HSCT, as well as from the respective control children and adult cohorts with SCD who received standard therapy. FEV1 will be reported in percentage. (References: Eur Respir J. Volume 40 Issue 6: pages 1324-1343, 2012 June 27; Am J Hematol. Volume 93 Issue 3: pages 408-415, 2018 March). |
Through study completion, an average of four years
|
|
Measurement of longitudinal change in FVC
Ramy czasowe: Through study completion, an average of four years
|
Measurements of forced volume capacity (FVC) based on the global lung index will be acquired from children with SCD receiving myeloablative curative therapies and adults with SCD receiving nonmyeloablative allo-HSCT, as well as from the respective control children and adult cohorts with SCD who received standard therapy. FVC will be reported in liters. (References: Eur Respir J. Volume 40 Issue 6: pages 1324-1343, 2012 June 27; Am J Hematol. Volume 93 Issue 3: pages 408-415, 2018 March). |
Through study completion, an average of four years
|
|
Percent predicted value of longitudinal change in FVC
Ramy czasowe: Through study completion, an average of four years
|
Percent predicted of forced volume capacity (FVC) on the global lung index will be acquired from children with SCD receiving myeloablative curative therapies and adults with SCD receiving nonmyeloablative allo-HSCT, as well as from the respective control children and adult cohorts with SCD who received standard therapy. FVC will be reported in percentage. (References: Eur Respir J. Volume 40 Issue 6: pages 1324-1343, 2012 June 27; Am J Hematol. Volume 93 Issue 3: pages 408-415, 2018 March). |
Through study completion, an average of four years
|
|
FEV1/FVC Ratio Percentage
Ramy czasowe: Through study completion, an average of four years
|
Percentage of FEV1/FVC ratio based on the global lung index will be acquired from children with SCD receiving myeloablative curative therapies and adults with SCD receiving nonmyeloablative allo-HSCT, as well as from the respective control children and adult cohorts with SCD who received standard therapy. (References: Eur Respir J. Volume 40 Issue 6: pages 1324-1343, 2012 June 27; Am J Hematol. Volume 93 Issue 3: pages 408-415, 2018 March). FEV1/FVC will be reported in percentage. |
Through study completion, an average of four years
|
|
Longitudinal change in eGFR
Ramy czasowe: Through study completion, an average of four years
|
Estimated GFR (eGFR) as a determinant of kidney disease will be collected from children with SCD receiving myeloablative curative therapies and adults with SCD receiving nonmyeloablative allo-HSCT, as well as from the respective control children and adult cohorts with SCD who received standard therapy. The eGFR will be tested as a linear variable and using eGFR Categories according to the KDIGO 2012 Guidelines (Table 5 - Reference: Kidney Int Suppl. Volume 3 Issue 1: pages 19-62, 2013 Jan) as follows: i.G1 >/ 90 mL/min/1.73m2 ii.G2 60 - 89 mL/min/1.73m2 iii.G3a 45 - 59 mL/min/1.73m2 iv.G3b 30 - 44 mL/min/1.73m2 v.G4 15 - 20 mL/min/1.73m2 vi.G5 < 15 mL/min/1.73m2 The standard technique of measured GFR will be used and reported in mL/min/1.73m2. |
Through study completion, an average of four years
|
|
Longitudinal change in albuminuria levels
Ramy czasowe: Through study completion, an average of four years
|
Data pertaining to persistent albuminuria (defined as >/ 30 mg/g creatinine on 2 evaluations) associated with a more rapid decline in eGFR on longitudinal follow-up (Reference: Blood Adv. Volume 4 Issue 7: pages 1501-1511, 2020 Apr 14) will be tested. Results will be reported in mg/g. |
Through study completion, an average of four years
|
|
Longitudinal change in TRJV in adults with SCD treated with nonmyeloablative allo HSCT in adults
Ramy czasowe: Through study completion, an average of four years
|
Improvement in TRJV in adults with SCD following HSCT will be acquired. Results will be reported in m/sec. |
Through study completion, an average of four years
|
|
Longitudinal change in SBP/DBP in adults with SCD treated with nonmyeloablative allo HSCT in adults
Ramy czasowe: Through study completion, an average of four years
|
Measurements of Systolic blood pressure (SBP)/Diastolic blood pressure (DBP) in adults with SCD following HSCT will be acquired. Results will be reported as a ratio (SBP (mmHg)/DBP (mmHg)). |
Through study completion, an average of four years
|
Współpracownicy i badacze
Współpracownicy
Śledczy
- Główny śledczy: Michael R DeBaun, MD, MPH, Vanderbilt University Medical Center
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby układu krążenia
- Choroby układu moczowo-płciowego u mężczyzn
- Choroby Urologiczne
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Choroby genetyczne, wrodzone
- Choroby Układu Oddechowego
- Choroby hematologiczne
- Anemia, hemolityczna, wrodzona
- Anemia, hemoliza
- Niedokrwistość
- Hemoglobinopatie
- Wrodzone, dziedziczne i noworodkowe choroby i nieprawidłowości
- Choroby hemowe i limfatyczne
- Choroby płuc
- Choroby serca
- Anemia, sierpowata komórka
- Choroby nerek
Inne numery identyfikacyjne badania
- 210806
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
This research study's sharing plan involves study data, publications, and outcomes. We will adhere to the NIH Public Access Policy (NOT-OD-08-033) and provide publications generated through funding by this project at the time the final, peer- reviewed papers are accepted for journal publication to the National Library of Medicine's PubMed Central, either through NIHMS (NIH Manuscript Submission) or through the Publisher. All applicable proposals, applications, and reports will include the PubMed Central number (PMCID) for all NIH-funded papers. All sequence data will be uploaded to database of Genotypes and Phenotype (dbGaP).
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .